Secondary Hypogonadism: Open Controversies in the Field

What Exactly Is Secondary Hypogonadism, and Why Is the Definition Contested?

Secondary hypogonadism arises from pituitary or hypothalamic dysfunction rather than testicular failure, producing low testosterone alongside low or inappropriately normal gonadotropins (LH and FSH). The mechanistic picture is clear. The diagnostic boundaries are not.

The Threshold Problem

The Endocrine Society's 2018 Clinical Practice Guideline defines biochemical hypogonadism as a total testosterone below 300 ng/dL confirmed on two morning samples [1]. The American Urological Association sets 300 ng/dL as its threshold as well [2]. The British Society for Sexual Medicine, by contrast, accepts 12 nmol/L (roughly 346 ng/dL) as the lower limit of normal for total testosterone [3].

That 46 ng/dL gap is clinically meaningful. A man sitting at 310 ng/dL qualifies for treatment in one country, not another.

The debate deepens when free testosterone enters the picture. Sex hormone-binding globulin (SHBG) levels vary by age, obesity, and liver disease, meaning two men with identical total testosterone readings may have very different biologically active fractions. The Endocrine Society recommends measuring free testosterone when total testosterone is borderline (200-400 ng/dL) and SHBG is suspected to be abnormal [1], but standardized free testosterone assays remain scarce outside academic centers.

Symptom-Lab Concordance: Do the Numbers Match the Patient?

A central controversy is whether biochemical criteria should gate treatment or whether symptomatic burden should carry equal weight. The European Male Ageing Study (N=3,369) found that a syndrome of three sexual symptoms (low libido, erectile dysfunction, infrequent morning erections) combined with total testosterone below 11 nmol/L (317 ng/dL) defined late-onset hypogonadism with the best specificity [4]. Yet clinicians regularly encounter men with testosterone at 280 ng/dL who report no symptoms, alongside men at 320 ng/dL with profound fatigue, depression, and sexual dysfunction.

The Endocrine Society guideline states directly: "We recommend against making a diagnosis of androgen deficiency in men with symptoms that could reflect hypogonadism but whose testosterone concentrations are consistently in the normal range" [1]. That instruction sounds clear. In practice, the "normal range" itself is the contested variable.

Cardiovascular Risk: The TRAVERSE Trial and What It Did (and Did Not) Settle

The cardiovascular safety of testosterone replacement therapy dominated clinical debate for over a decade. A 2010 trial by Basaria et al. (N=209 older men, mean age 74) was stopped early after testosterone gel produced excess cardiovascular events versus placebo [5]. That signal triggered FDA label changes and years of uncertainty.

What TRAVERSE Found

TRAVERSE (Testosterone Replacement in Men with Hypogonadism: Evaluation of Cardiovascular Events and Efficacy), published in the New England Journal of Medicine in 2023 (N=5,204, median follow-up 33 months), provided the largest randomized cardiovascular safety data set to date [6]. Testosterone gel 1.62% did not increase major adverse cardiovascular events (MACE: non-fatal MI, non-fatal stroke, cardiovascular death) versus placebo: 7.0% vs 7.3%, meeting the pre-specified non-inferiority margin.

That finding reassured many clinicians. The trial also produced a new concern. Atrial fibrillation occurred in 3.5% of testosterone-treated men versus 2.4% on placebo (hazard ratio 1.35, 95% CI 1.03-1.78, P=0.03) [6]. Pulmonary embolism was numerically higher in the testosterone arm as well, though that finding did not reach statistical significance.

Remaining Questions After TRAVERSE

The TRAVERSE population enrolled men aged 45-80 with pre-existing or high risk for cardiovascular disease and total testosterone 100-300 ng/dL. Younger men with secondary hypogonadism and no cardiovascular comorbidities were not well represented. Whether the atrial fibrillation signal applies to them is unknown.

Experts are also split on whether the non-inferiority finding should be interpreted as "testosterone is safe" or merely "testosterone does not make pre-existing cardiovascular disease materially worse in this specific population." The Endocrine Society's position, articulated in its 2018 guideline, was already cautious: "We suggest that clinicians discuss the risk-benefit ratio with patients and consider the cardiovascular risk profile before initiating testosterone therapy" [1]. TRAVERSE narrows but does not eliminate that uncertainty.

Fertility Preservation: TRT Versus Clomiphene, hCG, and Combination Protocols

For men of reproductive age with secondary hypogonadism, testosterone replacement creates a paradox. Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis, reducing intratesticular testosterone and halting spermatogenesis in most men within 3-4 months of initiation [7].

Why This Matters Clinically

Approximately 15% of couples experience infertility, and male factor contributes to 50% of those cases [8]. A 30-year-old man with idiopathic hypogonadotropic hypogonadism who wants children faces a choice his 60-year-old counterpart does not: accept temporary or potentially prolonged infertility in exchange for symptomatic relief from testosterone, or pursue fertility-preserving alternatives.

Clomiphene Citrate: Effective but Off-Label

Clomiphene citrate, an estrogen receptor antagonist, blocks estrogen-mediated negative feedback at the hypothalamus, increasing GnRH pulse frequency and downstream LH and FSH secretion. A randomized trial by Ramasamy et al. (N=100) showed clomiphene 25 mg every other day normalized testosterone in 75% of men with secondary hypogonadism without suppressing sperm production [9]. The drug is not FDA-approved for male hypogonadism. Prescribing it for this purpose is off-label, and insurance coverage is inconsistent.

hCG Monotherapy and Combination Approaches

Human chorionic gonadotropin (hCG), which mimics LH, stimulates Leydig cell testosterone production directly. Used alone or combined with recombinant FSH (for men who need spermatogenesis induction), hCG can normalize both serum testosterone and sperm parameters in men with secondary hypogonadism [10]. Long-term data on hCG monotherapy beyond 18 months remain sparse.

Some centers use hCG co-administration alongside testosterone to preserve testicular volume and residual spermatogenesis. A small trial by Hsieh et al. (N=26) showed that 500 IU hCG every other day maintained intratesticular testosterone during TRT [11]. This protocol is not addressed in the Endocrine Society's 2018 guideline, leaving prescribers without formal guidance.

The HealthRX clinical team uses a three-branch decision framework for men with secondary hypogonadism who express fertility intent:

1. Active conception attempt within 12 months: Start clomiphene citrate 25 mg every other day or hCG 2,000 IU three times weekly. Recheck testosterone and semen analysis at 3 months.
2. Fertility desired but not immediately: Discuss semen cryopreservation before any testosterone initiation, then reassess therapy choice with the patient after banking.
3. No fertility intent: Proceed with testosterone monotherapy per standard dosing, with clear documentation of the fertility discussion in the medical record.

Opioid-Induced Hypogonadism: A Widespread Problem With No Approved Treatment Protocol

Chronic opioid use suppresses GnRH release at the hypothalamus, producing a secondary hypogonadism that is biochemically indistinguishable from other hypogonadotropic states. The scale is large. A systematic review by Bawor et al. Found that up to 86% of men on long-term opioid therapy develop biochemical hypogonadism [12]. With more than 6.1 million Americans using prescription opioids chronically, the downstream hormonal burden is substantial [13].

Why Opioid-Induced Hypogonadism Is Underdiagnosed

Primary care providers managing chronic pain may not associate fatigue, depression, and sexual dysfunction with opioid use. The Endocrine Society guideline recommends screening men on chronic opioids for hypogonadism [1], yet no major pain society has embedded hormonal screening into its standard chronic pain monitoring protocol. The gap between the recommendation and its implementation in pain clinics is wide.

Treatment Dilemmas

Opioid dose reduction is the most direct intervention, but it is often clinically impractical in patients with undertreated pain or opioid use disorder. Switching opioid class (for example, buprenorphine, which may produce less hormonal suppression than full agonists) is a reasonable option [14], though head-to-head hormonal outcome data are limited.

Whether to start testosterone replacement in a man who cannot discontinue opioids is contested. Testosterone may improve quality of life and bone density. It does not address the underlying hypothalamic suppression and, because the axis remains suppressed, fertility cannot be preserved with standard clomiphene or hCG approaches as reliably as in men with other causes of secondary hypogonadism.

Age-Related Testosterone Decline: Disease or Normal Physiology?

Total testosterone declines approximately 1-2% per year in adult men after age 30, a well-replicated observation [15]. Whether this age-related decline constitutes a pathological state requiring treatment or a normal feature of aging is the broadest and most politically charged controversy in the field.

The Late-Onset Hypogonadism Debate

The term "late-onset hypogonadism" (LOH) implies a disease. Critics argue that applying the label to otherwise healthy aging men medicalizes normal physiology, exposes men to unnecessary cardiovascular and hematologic risks, and inflates pharmaceutical markets without proportionate benefit. Proponents counter that symptomatic men with confirmed low testosterone experience measurable improvements in bone density, lean body mass, sexual function, and mood with replacement therapy.

The TRAVERSE trial itself enrolled men with LOH as a significant component of its population. The non-inferiority MACE finding has been interpreted by some as supporting broader treatment and by others as applicable only to men with clear clinical and biochemical hypogonadism, not the borderline aging male.

What the Guidelines Currently Say

The Endocrine Society states: "We recommend against a general policy of offering testosterone therapy to all older men with low testosterone concentrations" [1]. The AUA guideline echoes this, recommending treatment for men with clear symptoms and confirmed biochemical deficiency, not for asymptomatic men with borderline values [2].

The tension is real. A 68-year-old man with testosterone of 285 ng/dL, low libido, osteopenia, and no absolute contraindications sits in the gray zone every major guideline acknowledges but none fully resolves.

The Estradiol Question: Monitoring and the Risk of Over-Suppression

Testosterone aromatizes to estradiol, and estradiol is not merely a byproduct. Men require estradiol for bone mineralization, libido, and erectile function. A landmark study by Finkelstein et al. (N=198) demonstrated that sexual dysfunction in testosterone-depleted men was mediated almost equally by estradiol deficiency as by testosterone deficiency itself [16].

Aromatase Inhibitor Use in Secondary Hypogonadism

Some clinicians prescribe anastrozole or letrozole to raise testosterone by blocking aromatization, or co-prescribe them with testosterone to prevent supraphysiologic estradiol. Both practices are off-label in men.

The Endocrine Society explicitly states it "recommends against the routine use of aromatase inhibitors in men with hypogonadism" because of concerns about bone density loss, negative effects on lipid profiles, and the risk of driving estradiol below physiologic levels [1]. Still, off-label aromatase inhibitor prescribing for men is common, particularly in direct-to-consumer testosterone clinics.

There is no randomized trial of sufficient size to define the optimal estradiol range in men on testosterone therapy. Serum estradiol targets cited in clinical practice (commonly 20-40 pg/mL) are based on observational data and expert opinion, not randomized controlled evidence.

Polycythemia, Hematocrit Monitoring, and When to Hold Therapy

Testosterone stimulates erythropoiesis, raising hematocrit. The Endocrine Society recommends checking hematocrit at 3-6 months after therapy initiation, then annually, and withholding therapy if hematocrit exceeds 54% [1]. This threshold is borrowed from the polycythemia vera literature, not from testosterone-specific outcomes data.

No large randomized trial has directly tested whether testosterone-induced polycythemia carries the same thrombotic risk as pathological polycythemia vera. The TRAVERSE trial reported hematocrit elevations but did not observe a statistically significant increase in venous thromboembolism, though the study may have been underpowered for that specific outcome [6].

Men receiving injectable testosterone esters (testosterone cypionate, enanthate) show larger hematocrit swings than those using daily gels or patches, owing to peak-trough pharmacokinetics. Whether the delivery route modifies thrombotic risk independently of mean hematocrit is an open question.

Bone Density: A Benefit Often Overlooked in the Controversy Discourse

While cardiovascular and fertility debates dominate the literature, bone loss in secondary hypogonadism receives less attention than it deserves. Men with hypogonadotropic hypogonadism have significantly lower bone mineral density than eugonadal age-matched controls, and fracture risk is elevated [17].

Does Testosterone Therapy Restore Bone?

A meta-analysis by Tracz et al. In the Journal of Clinical Endocrinology and Metabolism (11 randomized trials, N=492) found that testosterone therapy increased lumbar spine bone mineral density by 3.7% compared with placebo, with smaller but significant femoral neck gains [18]. Effect sizes were larger in men with more severe baseline deficiency.

Whether testosterone therapy reduces fracture incidence (not just bone mineral density) remains unproven. No adequately powered fracture-outcome trial exists for male hypogonadism. The Endocrine Society recommends baseline dual-energy X-ray absorptiometry (DXA) in hypogonadal men at risk for osteoporosis [1], but many clinicians skip this step in younger patients.

Diagnosing Secondary vs. Primary Hypogonadism: Gray Zones in Gonadotropin Interpretation

Distinguishing secondary from primary hypogonadism depends on gonadotropin levels. In primary (testicular) failure, LH and FSH are elevated because the pituitary responds to unrelenting low testosterone with compensatory secretion. In secondary hypogonadism, LH and FSH are low or inappropriately normal because the deficit begins upstream.

The "inappropriately normal" category creates diagnostic ambiguity. A man with total testosterone of 240 ng/dL and LH of 4 IU/L (within the lab reference range of 2-9 IU/L) has laboratory values that appear normal in isolation but may still represent secondary hypogonadism if the pituitary is failing to mount an adequate compensatory response.

Pulsatile LH secretion means that a single LH measurement captures only one point on a secretory wave. Some academic centers perform frequent LH sampling or GnRH stimulation testing to characterize hypothalamic-pituitary reserve more accurately [19]. These protocols are not standard outside referral centers and are essentially unavailable in primary care or telehealth settings.

Psychological and Quality-of-Life Outcomes: Real but Difficult to Quantify

Depression, cognitive slowing, and reduced vitality are common patient complaints in secondary hypogonadism. Testosterone therapy may improve these symptoms. The T-Trials (seven coordinated trials, N=788 men aged 65 or older, published in NEJM 2016) showed that testosterone gel improved sexual function and physical function but produced only modest and inconsistent improvements in vitality and mood over 12 months [20].

Measuring psychological outcomes in a condition where placebo response rates are high and symptom questionnaires (ADAM, AMS, IIEF) are subjective presents a persistent methodological challenge. Blinding is difficult in testosterone trials because participants often notice changes in libido, erythropoiesis, or body composition that reveal their treatment assignment.

The Endocrine Society acknowledges that the evidence supporting testosterone's effects on energy, mood, and cognitive function is "less strong" than for sexual and bone outcomes [1], a characterization that reflects the genuine uncertainty rather than dismissing the clinical observations patients consistently report.